U
Ultivue
Ultivue operates in the biotechnology industry
About Ultivue
Ultivue is a biotechnology startup that operates in the field of precision cancer therapies. The company's primary offering is its proprietary InSituPlex® technology, which allows scientists to generate high-confidence, quantitative insights into cancer tissues in a fraction of the time it would typically take. This technology works by amplifying antibody-linked tags to generate consistent signals from multiple markers simultaneously. This process turns tissues into actionable insights, aiding in the development of precision cancer therapies.
Read full description
Ultivue's clients are primarily scientists and researchers in the field of cancer research. The company's business model revolves around providing an "end-to-end" solution for these clients. This includes custom assay development, pre-optimized ready-to-use kits, specialized AI tools for image analysis, and full lifecycle image analysis services. By offering these services, Ultivue accelerates the research team's path to precise visualization and robust analysis of proteins in the tissue microenvironment.
The company's revenue comes from the sale of these services and products. The InSituPlex® platform and VUE panels provide researchers with pre-optimized yet configurable, as well as custom biomarker assays. These assays yield more precise insights than less quantitative methods quickly and cost-effectively, making them an attractive option for researchers.
In summary, Ultivue is a biotech startup that uses advanced technology and AI to aid in the development of precision cancer therapies. The company's unique offerings and end-to-end solutions make it a valuable partner in the field of cancer research.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Cambridge, United States
- Employees
- 31
- Open positions
- None listed
- Dealroom signal
- 64.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Ultivue.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Apr 2021 | $50M | $200M | ARCH Venture Partners · Applied Ventures · Tao Capital Partners · Pura Vida Investments | — |
| SERIES COther financing | Jun 2019 | $22M | $88M | ARCH Venture Partners · 6 Dimensions Capital · Yonghua Capital · Northpond Ventures | — |
Growth signals
Latest recorded traffic for Ultivue is 2.4K monthly website visits, down 31.4% over the last three months. Ultivue's team declined 8.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
ARCH Venture Partners
Applied Ventures
6 Dimensions Capital
Sangel Capital- FBFrontline BioVentures
Yonghua Capital
Series B and later4 investors entered at this stage
Northpond Ventures
Tao Capital Partners- PIPura Vida Investments
Ally Bridge Group
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ultivue on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ultivue’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.